Intracoronary thrombus formation results from the combined effects of platelet aggregation and fibrin formation. Fibrinogen plays a significant role in each of these components. Dethrombosis is a therapeutic approach that allows dissolution of a recent thrombus while avoiding the potent fibrinolytic therapies. The less aggressive strategies suggested to achieve dethrombosis are antifibrin, antiplatelet, and defibrinogenation. Glycoprotein receptor antagonists have been beneficial in patients undergoing percutaneous transluminal coronary angioplasty; however, little is known about their potency of inducing reperfusion in acute myocardial infarction. Early use of the strategies suggested to induce dethrombosis (antifibrin, antiplatelet, and defibrinogenation) may facilitate fibrinolysis and primary angioplasty and further induce reperfusion. Nevertheless, the theoretical arguments of facilitated thrombolysis (dethrombosis) have not yet been fruitful as a major clinical benefit except in patients undergoing primary percutaneous coronary intervention.
1. Scazziota A, Altman R. El mecanismo de la hemostasia normal. Cuadernos de trombosis. Infomed. Tomo I1999:9.
2.
2. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of rt-PA and monoclonal antiplatelet GP Ilb/IIIa antibody in a canine preparation. Circulation1988;77:670-670.
3.
3. Fuster V. Remodelado del trombo: punto clave en la progresion de la ateroesclerosis coronaria. Rev Esp Cardiol2000;53 (suppl 1):2-2.
4.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation1995;92:657-657.
5.
5. Lambert FM, van der Merkhof MD, Zijlstra F, et al. Abciximab in the treatment of AMI eligible for primary percutaneous transluminal coronary angioplasty. Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study. J Am Coll Cardiol1999;33:1528-1528.
6.
6. Altman R, Rouvier J, Scazziota A. Secondary prevention of myocardial infarction. Beneficial effect of combining oral anticoagulant plus aspirin: therapy based on evidence. Clin Appl Thromb Hemost2000;6:126-126.
7.
7. Van Belle E, Lablanche J, Bauters CH, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis. Circulation1998;97:28-28.
8.
8. Chesebro J. Direct thrombin inhibition superior to heparin during and after thrombolysis. Dose, duration and drug. Circulation1997;96:2118-2118.
9.
9. Antman EM, Giugliano RP, Gibso M, et al, for the TIMI-14 investigators. Abciximab facilitates the rate and extent of thrombolysis. Results of the TIMI-14 Trial. Circulation1999;99:2720-2720.
10.
10. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation1998;97:211-211.
11.
11. Coller BS. GP IIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost1997;78:730-730.
12.
12. ISIS-2 (second international study of infarct survival) collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17.187 cases of suspected AMI: ISIS-2. Lancet1988;2:349-349.
13.
13. Muhlestein JB.Fibrin-Fibrinogen and dethrombosis. Blood Coag Fibrinolysis1999;10 (Suppl 1):S59-S59.
14.
14. White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation1998;97:1632-1632.
15.
15. Brochier M, Raynaud P, Rioux P, et al. Thrombosis and thrombolysis in unstable angina. Am J Cardiol1991;68:105B-105B.
16.
16. Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial. Circulation1994;90:69-69.
17.
17. Cerceck B, Lew AS, Hod H, et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation1986;74:583-583.
18.
18. Agnelli G, Borm J, Cosmi B, et al. Effects of standard heparin and a low molecular heparin on fibrinolysis. Thromb Haemost1988;60:311-311.
19.
19. Verheugt FW, Liem A, Zijlstra F, et al. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the heparin in early patency (HEAP) pilot study. J Am Coll Cardiol1998;31:289-289.
20.
20. Braga JC, Estevez FP, Estevez JP, et al. Confirmation that heparin is an alternative means of promoting early reperfusion. Coronary Artery Dis1998;9:335-335.
21.
21. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial. Circulation1996;93:870-870.
22.
22. Narins CR, Hillegass WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation1996;93:667-667.
23.
23. Stadius ML. Angiographic monitoring of reperfusion therapy for AMI: TIMI grade 3 perfusion is the goal. Circulation1993;87:2055-2055.
24.
24. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res1994;74:1-1.
25.
25. Meyer B, Badimon J, Chesebro J, et al. Dissolution of mural thrombus by specific thrombin inhibition with rhirudin: Comparison with heparin and aspirin. Circulation1998;97:681-681.
26.
26. Mruk J, Zoldhelyi P, Webster M, et al. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus?: Effects of r-hirudin, heparin, or aspirin. Circulation1995;93:792-792.
27.
27. Wysokinski W, McBane R, Chesebro JH, et al. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost1996;76:1108-1108.
28.
28. Wu K, Willerson J. Monitoring platelet function in glycoprotein IIb/IlIa inhibitor therapy. Circulation2001;103:2528-2528.
29.
29. Shattil S, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm. Blood1998;91:2645-2645.
30.
30. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidin and clopidogrel. Ann Intern Med1998;129:394-394.
31.
31. Braunwald E, Maseri A, Armstrong PW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J1998;19 (Suppl D):D22-D22.
32.
32. Adgey A. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J1998;19 (Suppl D):D1O-D10.
33.
33. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet1997;349:1429-1429.
34.
34. PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IlIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina receptor suppression using integrelin therapy. N Engl J Med1998;339:436-436.
35.
35. PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein IIb/IlIa receptor with tirofibanin unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndromes management in patients limited by unstable signs and symptoms (PRISMPLUS) study investigators. N Engl J Med1998;338:1488-1488.
36.
36. Ambrose JA, Hawkey M, Badimon J, et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol2000;86:150-150.
37.
37. Theroux P, Willerson JT, Armstrong PW. Progress in the treatment of ACS. A 50-year perspective (1950-2000). Circulation2000;102:IV-2-IV-2.
38.
38. Kereiakes DJ. IIb/IIIa in Acute Coronary Syndromes: An Evidenced-Based Approach. Am Heart J2000:139 (Suppl).
39.
39. Coller BS. Augmentation of thrombolysis with antiplatelet drugs: Overview. Coronary Artery Dis1996;6:911-911.
40.
40. Collet J, Montalescot G, Lesty C, et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation2001;103:2328-2328.
41.
41. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in MI by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation1997;95:1755-1755.
42.
42. Kleiman N, Omain E, Califf R, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the TAMI 8 pilot study. JAm Coll Cardiol1993;22:381-381.
43.
43. Ohman EM, Kleiman NS, Gacioch G, et al, for the IMPACT-AMI investigators. Combined accelerated t-PA and platelet GP IIb/IIIa integrin receptor blockade with integrilin in AMI. Circulation1997;95:846-846.
44.
44. Moliterno DJ, Harrington RA, Krucoff MW, et al, for the PARADIGM investigators. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM trial [abstract]. Circulation1996; 94 (Suppl I):1-553.
45.
45. Verheugt FW, Ohman EM, Antman EM. Emergency room infusion of abciximab speeds up reperfusion in AMI eligible for primary PTCA. Eur Heart J1999;20:616-616.
46.
46. Ronner E, van der Wieken R, Slagboom T, et al. lIb/Illa receptor antagonists for failed rescue angioplasty. Circulation2000;101:214-214.
47.
47. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in AMI. Results from the SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol2000;36:1489-1489.
48.
48. GUSTO-IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tPA for MI. N Engl J Med1997;336:1621-1621.
49.
49. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in MI (TIMI) trial, phase I: A comparison between intravenous tPA and intravenous SK. Circulation1987;76:142-142.
50.
50. The GUSTO V investigators. Reperfusion therapy for AMI with fibrinolytic therapy and platelet glycoprotein Ilb/IIIa inhibition: the GUSTO V randomized trial. Lancet2001;357:1905-1905.
51.
51. Verheugt FW. GUSTO V: The bottom line of fibrinolytic reperfusion therapy. Lancet2001;357:1898-1898.
52.
52. The assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 trial in AMI. Lancet2001;358:605-605.
53.
53. Bell WR. Defibrinogenating enzymes. Drugs1997;54 (Suppl 3):18-18.
